United Arab Emirates Glucoamylase Market Size & Outlook, 2026-2034
United Arab Emirates Glucoamylase Market Insights
- Reed Intelligence analysis indicates that the United Arab Emirates Glucoamylase Market size, valued at USD 44.84 Million in 2025, is expected to expand to USD 79.82 Million by 2034.
- The United Arab Emirates market is forecasted to expand at a CAGR of 6.63% spanning 2026–2034.
- Microbial Glucoamylase held the leading position among Type segments in 2025, based on market size.
- Genetically Engineered Glucoamylase is projected to post the fastest growth rate, sustaining its position as the most attractive Type segment during the forecast horizon.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, United Arab Emirates represented 4.27% of the overall global Glucoamylase Market size.
- United States is projected to lead the global Glucoamylase Market size by 2034.
- Across Middle East and Africa, United Arab Emirates is anticipated to hold the dominant position in market size by 2034.
- Egypt is forecasted to expand at the fastest pace in Middle East and Africa, attaining USD 19.83 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 44.84 Million |
| Market Size In 2034 | USD 79.82 Million |
| Largest segment | Microbial Glucoamylase |
| Units | Revenue in USD Million |
| CAGR | 6.63% (2026-2034) |
| Segmnetation Covered | |
| Type |
|
| Application |
|
| End-Use Industry |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Arab Emirates Glucoamylase Market Type 2026-2034 (USD Million)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microbial Glucoamylase | XX.x | XX.x | XX.x | 21.43 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Plant-Based Glucoamylase | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Genetically Engineered Glucoamylase | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Arab Emirates Glucoamylase Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food & Beverage Processing | XX.x | XX.x | XX.x | 21.64 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bioethanol Production | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal Feed | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Arab Emirates Glucoamylase Market End-Use Industry 2026-2034 (USD Million)
| End-Use Industry | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food & Beverage Industry | XX.x | XX.x | XX.x | 19.98 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Energy & Biofuel Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceutical & Biotechnology Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Agriculture Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
